<DOC>
	<DOC>NCT02015234</DOC>
	<brief_summary>This is a Phase 3, open-label, extension trial designed to evaluate the long-term safety over 12 months of TNX-102 SL tablets taken daily at bedtime for the treatment of FM. Patients recruited into this trial are those who have successfully completed the double-blind study, TNX-CY-F202 (F202). Patients will not be made aware of the therapy they received during the double-blind study.</brief_summary>
	<brief_title>12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients</brief_title>
	<detailed_description>The study will consist of 7 clinic visits, including Screening/Baseline Visit 1 (Day 0, which is anticipated to be the same date as Visit 6 in F202), visits after 1, 3, 6, 9, and 12 months of treatment (Visits 2-6), and a Follow-up Visit (Visit 7) scheduled within one month after stopping study drug treatment. Primary: The primary objective of the study is to evaluate the long-term safety of TNX-102 SL tablets taken daily at bedtime over 12 months in patients with FM who have completed Study TNX-CY-F202 Secondary: The secondary objective is to evaluate the long-term efficacy of TNX-102 SL tablets taken daily at bedtime to control symptoms of FM</detailed_description>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Cyclobenzaprine</mesh_term>
	<criteria>1. The patient met all prior inclusion and exclusion requirements for Study F202 originally, and has had no intervening medical conditions, increased suicidal ideation, or requirements for concomitant medications that preclude exposure to TNX102 SL or enrollment in the extension study. 2. The patient completed expected dosing in F202 defined as taking study medication up to Week 12, with at least 70% compliance with medication usage (based on responses from daily IVRS calls recorded during the F202 study) and no major protocol violations. 3. The patient has provided written informed consent to participate in this extension protocol.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>TNX-102 SL</keyword>
	<keyword>bedtime</keyword>
	<keyword>sublingual</keyword>
	<keyword>12-month</keyword>
	<keyword>long term safety</keyword>
	<keyword>long term efficacy</keyword>
	<keyword>Fibromyalgia</keyword>
</DOC>